Clinical Trials Logo

Pancreatic Cancer clinical trials

View clinical trials related to Pancreatic Cancer.

Filter by:

NCT ID: NCT06244771 Recruiting - Colorectal Cancer Clinical Trials

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

PROSPER
Start date: February 12, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid tumors will be evaluated.

NCT ID: NCT06239194 Recruiting - Breast Cancer Clinical Trials

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Start date: June 12, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

NCT ID: NCT06238479 Recruiting - Prostate Cancer Clinical Trials

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

Start date: March 5, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.

NCT ID: NCT06224387 Recruiting - Clinical trials for Non-small Cell Lung Cancer

CTS2190 Phase I /II Clinical Study in Patients

Start date: June 26, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a first in human study in patients with advanced or metastatic solid tumors. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific tumor types. The study drug, CTS2190, is a PRMT1 inhibitor administered orally. The study is planned to treat up to 224 participants.

NCT ID: NCT06202014 Recruiting - Pancreatic Cancer Clinical Trials

Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPC

Start date: January 31, 2024
Phase: Phase 2
Study type: Interventional

This is a single-arm prospective phase II clinical trial to investigate the efficacy and safety of concurrent radiotherapy with envafolimab and capecitabine in locally advanced pancreatic cancer.Eligibility patients will receive intensity-modulated radiotherapy(IMRT)or volumetric modulated arc therapy(VMAT) to pancreatic lesions,metastatic lymph nodes and high-risk lymphatic drainage areas,concurrent with and followed by envafolimab and capecitabine.

NCT ID: NCT06196788 Recruiting - Pancreatic Cancer Clinical Trials

Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer

PTCA199-9
Start date: March 1, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of gemcitabine and nab-paclitaxel venous injection plus transcatheter arterial infusion to Patients with Advanced Pancreatic Cancer.

NCT ID: NCT06177522 Recruiting - Pancreatic Cancer Clinical Trials

Adbelizumab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer

Start date: December 2023
Phase: Phase 2
Study type: Interventional

Clinical Study on the Safety and Efficacy of the efficacy and safety of adbelizumab combined with chemotherapy for neoadjuvant treatment of resectable pancreatic cancer

NCT ID: NCT06168812 Recruiting - Pancreatic Cancer Clinical Trials

A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer

Start date: December 5, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out how effective and safe glipizide is for lowering blood sugar in people with pancreatic cancer.

NCT ID: NCT06159478 Recruiting - Pancreatic Cancer Clinical Trials

Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)

Perfume
Start date: March 29, 2023
Phase: Phase 2
Study type: Interventional

This study is an open-label, parallel, 2-cohort, multicenter, investigator-initiated Phase 2 trial to evaluate the efficacy and safety of binimetinib in patients with advanced or recurrent low-grade glioma or pancreatic cancer harboring BRAF fusion/rearrangement.

NCT ID: NCT06151262 Recruiting - Pancreatic Cancer Clinical Trials

A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer

Start date: January 20, 2024
Phase: Phase 2
Study type: Interventional

To observe the incidence of chemotherapy-induced myelosuppression and the safety of Trilaciclib combined with mFOLFIRINOX in patients with advanced pancreatic cancer receiving first-line treatment.